18FDG imaging of giant cell arteritis: Usefulness of whole-body plus brain PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 7, 2004, Pages 1055-1056

  Belhocine, Tarik ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

AORTA ARCH SYNDROME; BRAIN MAPPING; DIAGNOSTIC IMAGING; GIANT CELL ARTERITIS; LETTER; MONITORING; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY SCINTISCANNING; ADOLESCENT; ADULT; ARTERIOSCLEROSIS; ARTERITIS; ARTERY; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; METABOLISM; METHODOLOGY; NOTE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TEMPORAL ARTERITIS; VASCULITIS;

ADOLESCENT; ADULT; ARTERIES; ARTERIOSCLEROSIS; ARTERITIS; BRAIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAKAYASU'S ARTERITIS; TEMPORAL ARTERITIS; TOMOGRAPHY, EMISSION-COMPUTED; VASCULITIS;

EID: 3142736389     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1547-4     Document Type: Letter

References (13)

1. Weiner SM, Vaith P, Walker UA, Brink I. Detection of alterations in brain glucose metabolism by positron emission tomography in Takayasu's arterities. Eur J Nucl Med Mol Imaging 2004; 31:300-302.
2. Belhocine T, Blockmans D, Hustinx R, Vandevivere J, Mortelmans L. Imaging of large vessel vasculitis with 18FDG PET: illusion or reality? A critical review of the literature. Eur J Nucl Med Mol Imaging 2003; 30:1305-1313.
3. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23:1641-1674.
4. 18Ffluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies. Mol Imaging Biol 2002; 4:359-362.
5. Blockmans D, Maes A, Stroobants S, Nuyts J, Bormans G, Knockaert D, Bobbaers H, Mortelmans L. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxf) 1999; 38:444-447.
6. Hara M, Goodman PC, Leder RA. FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr 1999; 23:16-18.
7. Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 2002; 16:515-525.
8. Wildhagen K, Meyer GJ, Stoppe G, Heintz P, Deicher H, Hundeshagen H. PET and MR imaging in a neuro-Behqet syndrome. Eur J Nucl Med 1999; 15:764-766.
9. Weiner SM, Otte A, Schumacher M, Juengling FD, Brink I, Nitzsche EU, Peter HH, Kreisel W. Neuro-Beḩet's syndrome in a patient not fulfilling criteria for Beḩet's disease: clinical features and value of brain imaging. Clin Rheumatol 2000; 19:231-234.
10. Weiner SM, Otte A, Schumacher M, Brink I, Juengling FD, Sobanski T, Nitzsche EU, Peter HH. Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric lupus erythematosus. Lupus 2000; 9:386-389.
11. Dubey N, Miletich RS, Wasay M, Mechtler LL, Bakshi R. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci 2002; 205:77-81.
12. 18F-fluorodeoxyglucose-positron emission tomography: a new explorative perspective. Exp Gerontol 2003; 38:463-470.
13. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomography imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002; 32:47-59.